GlaxoSmithKline's Use of EpiAirway in Cigarette Smoke Exposure Research

Two recent GlaxoSmithKline (GSK) scientific posters presented at the 2008 American Thoracic Society Meeting summarized GSK's research on the effects of cigarette smoke exposure, and also highlighted the use of EpiAirway, MatTek's human airway in vitro tissue equivalent, in this research.

To receive full copies of these two posters in PDF format, simply fill out the MatTek Information Request Form (link below) and put the words "GSK posters" in the "Comments" of the form. The full posters will be emailed to you in one business day or less.

The title of each GSK poster and a brief summary is listed below:

EXPOSURE OF A MULTI-CELLULAR IN VITRO MODEL OF HUMAN AIRWAY TISSUE TO WHOLE CIGARETTE SMOKE
This study demonstrated that MatTek's EpiAirwayFT ("full thickness") human airway in vitro tissue model is a more appropriate physiological model of lung parenchymal tissue than monolayer airway epithelial cell cultures for the analysis of the mechanisms associated with smoking related disease such as inflammation and tissue remodeling and repair.

CELLULAR RESPONSES OF PRIMARY HUMAN BRONCHIAL EPITHELIAL CELLS TO WHOLE CIGARETTE SMOKE EXPOSURE
This study demonstrated that MatTek's EpiAirway human airway in vitro tissue model combined with the Vitrocell system provided a more physiologically relevant model for studying the effects of cigarette smoke exposure.

Request an Electronic Copy (PDF format) of this Technical Paper